The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial
Abstract
Recent studies reported symptomatic overlap between attention deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD). Methylphenidate (MPH) is the most efficient treatment for ADHD. We assessed the efficacy and tolerability of MPH treatment in adolescent females who met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for both disorders. Fourteen BPD/ADHD female adolescents aged 14-19 years were treated with MPH for 12 weeks, targeting ADHD, BPD symptoms, and aggressive behavior, as rated by ADHD-rating scale (ADHD-RS) and Clinical Global Impression-Severity (CGI-S) scale for BPD and aggressive behavior severity. A significant improvement was detected in both ADHD and BPD severity (baseline vs. end point, ADHD-RS: 33.1+/-4.8 vs. 17.6+/-5.2, P<0.001; BPD CGI-S: 4.6+/-0.8 vs. 3.4+/-0.8, P<0.0005, respectively) as well as in aggressive behavior (Aggression CGI-S: 3.5+/-1.3 vs. 1.8+/-0.5, P<0.001). MPH was well tolerated. MPH may be useful and well tolerated in treating some shared symptoms of ADHD and BPD among female adolescents. Controlled studies are needed to substantiate these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, individuals presenting with a diagnosis of personality disorder who present with the ADHD syndrome that started in childhood will in many cases benefit from pharmacological treatments for ADHD [232,233].”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [232]
Citations
Cites
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
BARKLEY, R. A., FISCHER, M., EDELBROCK, C. S., & SMALLISH, L. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00007 · Cited by 1,507
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.6.885 · Cited by 1,421 · cited 1×
“For this purpose, they used the Wender Utah Rating Scale (WURS), a 61-item scale for assessing adult ADHD that evaluates ADHD-relevant childhood behaviors and symptoms, retrospectively (Ward et al., 1993).”
MethodMethylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder
Aron, A. R., Dowson, J. H., Sahakian, B. J., & Robbins, T. W. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00609-7 · Cited by 391
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND COMORBIDITY
Spencer, T., Biederman, J., & Wilens, T. (1999) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70163-2 · Cited by 270
Psychiatric interviews suitable for use in research with children and adolescents.
Orvaschel, H. (1985) · PubMed · Cited by 238
Philipsen, A. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-1006-2 · Cited by 184
Fossati, A., Novella, L., Donati, D., Donini, M., & Maffei, C. (2002) · Comprehensive Psychiatry · doi:10.1053/comp.2002.34634 · Cited by 182
Ross, R. G. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1149 · Cited by 167
LAMPE, K., KONRAD, K., KROENER, S., FAST, K., KUNERT, H. J., & HERPERTZ, S. C. (2007) · Psychological Medicine · doi:10.1017/s0033291707000517 · Cited by 147
Research works printed but not linked: 2
- Hooberman, 1984, J Clin Psychiatry, 45, 441
- Orvaschel, 1985, Psychopharmacol Bull, 21, 737
Cited by
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“Importantly, individuals presenting with a diagnosis of personality disorder who present with the ADHD syndrome that started in childhood will in many cases benefit from pharmacological treatments for ADHD [232,233].”
Top-Down Dysregulation—From ADHD to Emotional Instability
Petrovic, P., & Castellanos, F. X. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00070 · Cited by 179
“…on emotional dysregulation behaviors in ASPD and CD (Kaplan et al., 1990; Brown et al., 1991; Klein et al., 1997; Connor et al., 2000) as well as BPD (Schulz et al., 1988; Golubchik et al., 2008; Prada et al., 2015; although see Schulz et al. (1988) for possible issue with schizotypal comorbidity).”
BackgroundAsherson, P. J., Young, A. H., Eich‐Höchli, D., Moran, P., Porsdal, V., & Deberdt, W. G. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.915800 · Cited by 162
Matthies, S. D., & Philipsen, A. (2014) · Borderline Personality Disorder and Emotion Dysregulation · doi:10.1186/2051-6673-1-3 · Cited by 110
Weiner, L., Perroud, N. A., & Weibel, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s192871 · Cited by 104
Metadata
- Authors
- Golubchik, P., Sever, J., Zalsman, G., & Weizman, A.
- Affiliations
- Geha Mental Health Center (IL)
- Tel Aviv University (IL)
- Corresponding author
- Golubchik, Pavel
- Venue
- International Clinical Psychopharmacology
- Published
- 2008-07
- Volume
- 23
- Issue
- 4
- Pages
- 228-231
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2034420993
- Cited by
- 36
- References
- 22
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 3
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- methylphenidate, attention deficit hyperactivity disorder, borderline personality disorder, adolescent girls, aggression, tolerability
- MeSH terms
- Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Borderline Personality Disorder, Female, Humans, Methylphenidate, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. https://app.cochat.ai/papers/10.1097/yic.0b013e3282f94ae2
- The paper
- Golubchik, P., Sever, J., Zalsman, G., & Weizman, A. (2008). Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e3282f94ae2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.